@article {7514,
	title = {Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: Use of {\textquotedblleft}progression-free survival 2{\textquotedblright} as a clinical trial end-point},
	journal = {Haematologica},
	volume = {100},
	year = {2015},
	note = {Cited By :8Export Date: 21 February 2017},
	month = {2015},
	pages = {e328 - e330},
	keywords = {Lenalidomide, Maintenance, MM-015, Newly diagnosed multiple myeloma (NDMM), PFS2},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84938558814\&doi=10.3324\%2fhaematol.2014.120790\&partnerID=40\&md5=d09ad6671020046ddd05474db7d9f8aa},
	author = {Dimopoulos, M.A. and Petrucci, M.T. and Fo{\`a}, R. and Catalano, J. and Kropff, M. and Terpos, E. and Zhang, J. and Grote, L. and Jacques, C. and Palumbo, A.}
}
